Dialysis patients may get better vaccine protection with a common transplant drug

NCT ID NCT07587801

Not yet recruiting Disease control Sponsor: Central Adelaide Local Health Network Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a short course of the drug sirolimus (Rapamycin) can improve how well older adults on hemodialysis respond to flu and RSV vaccines. Sixty participants will receive the vaccines plus sirolimus at different times. The goal is to see if this approach strengthens immune memory against these viruses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus (Rapamycin)
What this could lead to: If it works, this could point toward a way to improve vaccine protection for people with weakened immune systems, like those on dialysis.
What could go wrong: This is a small, early-phase trial (60 people) and the drug may not improve vaccine response or could cause side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMODIALYSIS PATIENTS OLDER ADULTS VACCINE IMMUNE RESPONSE

Contacts and locations

Locations

Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.